DEPDC1 is up-regulated in uterine corpus endometrial cancer

doi:10.16352/j.issn.1001-6325.2023.09.1399

Abstract

Abstract: Objective To explore the expression and function of DEP domain containing 1 (DEPDC1) in uterine corpus endometrial cancer(UCEC). Methods The Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases were used to analyze the expression of DEPDC1 mRNA in normal endometrial tissues and UCEC tissues, the relationship with patient clinicopathological parameters and prognosis. Immuno-histochemistry (IHC), Western blot and RT-qPCR were used to detect the expression of DEPDC1 in UCEC cell lines and tissue. The CCK-8 assay, colony formation assay, and tumor xenograft were used to investigate the effect of DEPDC1 on cancer proliferation. Results DEPDC1 mRNA was up-regulated in UCEC (P＜0.001) and was correlated with the clinical stages (P＜0.001), tissue differentiation (P＜0.05) and histological type(P＜0.001) of UCEC. Compared with the DEPDC1 mRNA low expression patients, the patients with high expression of DEPDC1 showed lower disease-specific survival(DSS) and progress-free interval (PFI) (P＜0.01). The IHC, Western blot, and RT-qPCR showed that DEPDC1 was up-regulated both in UCEC tissue and cell lines. Down regulation of DEPDC1 inhibited the colony formation, invasion and tumor sphere formation, cell proliferation rate, and tumourigenesis in vivo. Conclusions DEPDC1 is up-regulated in UCEC that is correlated with the malignant progression and poor prognosis of UCEC.

Key words: uterine corpus endometrial cancer, DEP domain containing 1 (DEPDC1), proliferation

CLC Number:

R737.33

YANG Tingting, HUANG Jie, GUO Jianxin, HAN Jian. DEPDC1 is up-regulated in uterine corpus endometrial cancer[J]. Basic & Clinical Medicine, 2023, 43(9): 1399-1407.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.09.1399

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I9/1399

References

[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66: 115-132.
[2]Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67: 7-30.
[3]Crosbie EJ, Kitson SJ, Mcalpine JN, et al. Endometrial cancer[J]. Lancet, 2022, 399: 1412-1428.
[4]Legge F, Restaino S, Leone L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment[J]. Int J Gynecol Cancer, 2020, 30: 193-200.
[5]Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer[J]. N Engl J Med, 2019, 380: 2317-2326.
[6]Kanehira M, Harada Y, Takata R, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis[J]. Oncogene, 2007, 26: 6448-6455.
[7]Feng X, Zhang C, Zhu L, et al. DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma[J]. Oncotarget,2017, 8: 63605-63619.
[8]Shen L, Li H, Liu R, et al. DEPDC1 as a crucial factor in the progression of human osteosarcoma[J]. Cancer Med, 2023, 12: 5798-5808.
[9]Qu D, Cui F, Lu D, et al. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis[J]. Cancer Sci,2019, 110: 157-165.
[10]Wang Q, Jiang S, Liu J, et al. DEP Domain containing 1 promotes proliferation, invasion, and epithelial-mesenchymal transition in colorectal cancer by enhancing expression of suppressor of zest 12[J]. Cancer Biother Radiopharm, 2021, 36: 36-44.
[11]贺晶,李艳,王延峰,等. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42: 1356-1361.
[12]王晴晴,李爱丽,黄国锦. 含DEP结构域的蛋白质1在癌症发生发展中的作用[J]. 广西医学, 2016, 38: 1740-1743.

[1]	PAN Shan, LIN Kengqiang, CHEN Shuxing. Pemetrexed inhibits the proliferation of lung adenocarcinoma cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(9): 1359-1363.
[2]	LIANG Huiyong, WEI Qiuhui, DING Ya, PENG Xiaoqing, YAO Jing, SU Qijian. Cordycepin inhibits proliferation of human keratinocyte cell line HaCaT induced by TNF-α [J]. Basic & Clinical Medicine, 2023, 43(9): 1390-1393.
[3]	HUANG Jie, LI Runbo, GUO Jianxin, HAN Jian. Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3 [J]. Basic & Clinical Medicine, 2023, 43(8): 1247-1253.
[4]	ZHANG Peibo, LI Yi. Total flavonoids of Hippophae rhamnoides L. inhibits proliferation of bladder cancer cell line T24 [J]. Basic & Clinical Medicine, 2023, 43(7): 1122-1126.
[5]	TANG Yijun, WANG Wenlong, LI Jiangli, YANG Huan, SUN Jing. LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(7): 1023-1029.
[6]	JIN Xiaoxia, LU Xiaoyun, LIU Yushan, LIANG Lina. Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration [J]. Basic & Clinical Medicine, 2023, 43(7): 1090-1096.
[7]	ZENG Yankun, HONG Xiaoying, CHEN Qinglin. Down-regulation of BECN1 inhibits the proliferation, invasion and migration of human leukemia cell line THP-1 [J]. Basic & Clinical Medicine, 2023, 43(7): 1104-1109.
[8]	SU Jingyu, ZHANG Zhenxi, DU Wenjing. Effect of TPX2 expression on prognosis of pancreatic carcinoma [J]. Basic & Clinical Medicine, 2023, 43(6): 875-881.
[9]	HOU Mengjie, ZHAO Na, HUANG Fuqiang, WANG Yanan, LIU Fangming. Apolipoprotein E negatively regulates Golgi membrane protein 73 to inhibit the proliferation of mouse liver cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(5): 762-770.
[10]	LIU Yue, CAO Yang, GU Weiying, SHANG Limei, LIU Yan. Decitabine combined with arsenic trioxide inhibits proliferation and promotes apoptosis of acute myeloid leukemia cell lines [J]. Basic & Clinical Medicine, 2023, 43(4): 608-614.
[11]	WANG Fangfang, CAO Huiyuan, WANG Jing, WANG Ning, HUANG Guoliang. Up-regulation of miR-200c-5p inhibits proliferation of human colorectal cancer cell line SW480 [J]. Basic & Clinical Medicine, 2023, 43(2): 241-245.
[12]	YANG Liangquan, YU Miao, JIANG Qian, ZHANG Minghui, YANG Haisong. miR-504 regulates proteasome activator and inhibits the proliferation and migration of breast cancer cell line MCF-7 [J]. Basic & Clinical Medicine, 2023, 43(1): 95-101.
[13]	HE Jing, LI Yan, WANG Yan-feng, BAO Hui. Up-expression of FABP4 promotes the proliferation and migration of endometrial cancer cell line HEC-1-A [J]. Basic & Clinical Medicine, 2022, 42(9): 1356-1361.
[14]	ZHANG Xiao-lei, LIU Jing, LI Chao-ping. Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D [J]. Basic & Clinical Medicine, 2022, 42(9): 1350-1354.
[15]	WANG Juan, ZHANG Xiao-yan, ZHU Ai-hua, YU Hong-bo, FAN Xin-dan, TANG Chun-hui, YAO Xiu-fang. High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients [J]. Basic & Clinical Medicine, 2022, 42(9): 1391-1399.